Mylan Inc. announced this morning that it had agreed to buy certain women’s health care businesses from Famy Care Ltd., based in Mumbai, India, for as much as $800 million.
The Cecil-based generic drug giant agreed to pay $750 million in cash plus contingent payments of up to $50 million if Famy Care fulfills certain regulatory and development milestones, Mylan said.
Privately-held Famy Care is a global leader in generic oral contraceptives.
“The Famy Care businesses will make Mylan a hormonal contraceptives leader in high-growth emerging markets around the world,” Mylan said.
Since 2008, Mylan and Famy Care have had a partnership under which Famy Care develops and supplies oral contraceptives to Mylan for distribution in the U.S. and certain other markets.
The latest transaction will complement Mylan’s pending acquisition of a major chunk of Abbott Laboratories’ specialty and branded generics business overseas, the company said. As part of the Abbott deal, Mylan plans to reincorporate in the Netherlands to lower its tax bill in a process known as an inversion. The acquisition, valued at $5.3 billion when it was announced last summer, is expected to close this quarter.
Read More
The deal with Famy Care, which will add about 900 employees to Mylan’s operations, is expected to close in the second half this year.
The acquisition comes on the heels of Mylan’s roughly $1.7 billion acquisition of Strides Arcolab’s Agila Specialties injectable drug unit in India in 2013.
Patricia Sabatini: psabatini@post-gazette.com or 412-263-3066.


Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.